{"nctId":"NCT00949650","briefTitle":"BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation","startDateStruct":{"date":"2009-08-14","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung","Adenocarcinoma"],"count":345,"armGroups":[{"label":"BIBW 2992","type":"EXPERIMENTAL","interventionNames":["Drug: BIBW 2992"]},{"label":"Cisplatin/Pemetrexed","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin"]}],"interventions":[{"name":"Pemetrexed","otherNames":[]},{"name":"BIBW 2992","otherNames":[]},{"name":"Cisplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.\n* Epidermal Growth Factor Receptor mutation detected by central laboratory analysis of tumour biopsy material.\n* Measurable disease according to RECIST 1.1.\n* Eastern Cooperative Oncology Group score of 0 or 1.\n* Age \\>/= 18 years.\n* Life expectancy of at least three months.\n* Written informed consent that is consistent with International Conference on Harmonisation-Good Clinical Practice guidelines.\n\nExclusion criteria:\n\n* Prior chemotherapy for relapsed and/or metastatic NSCLC. Neoadjuvant/adjuvant chemotherapy is permitted if at least 12 months has elapsed between the end of chemotherapy and randomisation.\n* Prior treatment with Epidermal Growth Factor Receptor targeting small molecules or antibodies.\n* Radiotherapy or surgery (other than biopsy) within 4 weeks prior to randomisation.\n* Active brain metastases\n* Any other current malignancy or malignancy diagnosed within the past five years\n* Known pre-existing interstitial lung disease.\n* Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom.\n* History or presence of clinically relevant cardiovascular abnormalities.\n* Any other concomitant serious illness or organ system dysfunction.\n* Adequate absolute neutrophil count and platelet count\n* Adequate liver and kidney function\n* Active hepatitis B infection, active hepatitis C infection or known HIV carrier.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) Time","description":"PFS was defined as time from randomisation to disease progression or death whichever occured first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Median time results from unstratified Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.17","spread":null},{"groupId":"OG001","value":"6.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Objective Response (OR)","description":"OR was defined as Complete Response (CR) or Partial Response (PR). Assessed by central independent review according to RECIST 1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"22.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control (DC)","description":"DC was defined as a patient with OR or Stable Disease (SD). Assessed by central independent review according to the RECIST 1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":null},{"groupId":"OG001","value":"80.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Time","description":"OS was defined as time from randomisation to death.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.16","spread":null},{"groupId":"OG001","value":"28.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Tumour Shrinkage","description":"Tumour shrinkage was calculated as the minimum Sum of Diameters (SoD) of target lesions from all post-baseline tumour assessments, as read by the central independent review. The mean of these minimum values were presented after adjusting for baseline SoD, EGFR mutation group and race.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.19","spread":"1.12"},{"groupId":"OG001","value":"43.00","spread":"1.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Because the PFS was longer for patients in the Afatinib arm than for patients in the chemotherapy arm, the period of data collection for ECOG status and body weight continued for a longer time in the Afatinib arm.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.95","spread":"3.91"},{"groupId":"OG001","value":"-2.68","spread":"2.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.19","spread":"5.36"},{"groupId":"OG001","value":"-0.29","spread":"4.02"}]}]}]},{"type":"SECONDARY","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","description":"ECOG PS measured on 6 point scale to assess participant's performance status. 0=Fully active, able to carry on all pre-disease activities without restriction.\n\n1. Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work.\n2. Ambulatory (\\>50 percent of waking hours), capable of all self-care, unable to carry out any work activities.\n3. Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours.\n4. Completely disabled, cannot carry on any self-care, totally confined to bed or chair.\n5. Dead.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (HRQOL): Time to Deterioration in Coughing","description":"HRQOL was measured by European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire C30 (QLQ-C30) and its lung cancer specific module LC13 (QLQ-LC13). Analysis for cough is based on QLQ-LC13 question 1. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.97","spread":null},{"groupId":"OG001","value":"8.02","spread":null}]}]}]},{"type":"SECONDARY","title":"HRQOL: Time to Deterioration in Dyspnoea","description":"HRQOL was measured by EORTC QLQ-C30 and its lung cancer specific module QLQ-LC13. Analysis for dyspnoea is based on composite of QLQ-LC13 questions 3-5. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.41","spread":null},{"groupId":"OG001","value":"2.86","spread":null}]}]}]},{"type":"SECONDARY","title":"HRQOL: Time to Deterioration in Pain","description":"HRQOL was measured by EORTC QLQ-C30 and its lung cancer specific module QLQ-LC13. Analysis for pain is based on composite of QLQ-C30 questions 9 and 19. Time to deterioration was defined as the time from randomisation to a score increased (worsened) by at least 10 points from baseline (0-100 point scale). Patients were considered deteriorated at time of death. Median time results from unstratified Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":null},{"groupId":"OG001","value":"3.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Plasma Concentrations of Afatinib at Day 22","description":"Trough plasma concentrations of Afatinib at Day 22 (course 2, visit 1) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"21.8","spread":"36.6"},{"groupId":"OG002","value":"28.0","spread":"85.0"},{"groupId":"OG003","value":"29.9","spread":"46.1"}]}]}]},{"type":"SECONDARY","title":"Trough Plasma Concentrations of Afatinib at Day 29","description":"Trough plasma concentrations of Afatinib at day 29 (course 2, visit 2) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"28.0","spread":"82.4"},{"groupId":"OG002","value":"25.8","spread":"69.5"},{"groupId":"OG003","value":"29.6","spread":"79.2"}]}]}]},{"type":"SECONDARY","title":"Trough Plasma Concentrations of Afatinib at Day 43","description":"Trough plasma concentrations of Afatinib at Day 43 (course 3, visit 1) after multiple daily dosing of 40 mg Afatinib and after dose escalation to 50 mg or dose reduction to 30 mg or 20 mg.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":"260"},{"groupId":"OG001","value":"24.7","spread":"63.9"},{"groupId":"OG002","value":"23.5","spread":"66.2"},{"groupId":"OG003","value":"27.5","spread":"64.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":72,"n":229},"commonTop":["Diarrhoea","Rash","Nausea","Paronychia","Decreased appetite"]}}}